Tamsulosin Hydrochloride Capsule
Product Images NDC 70518-0179

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 70518-0179). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for Tamsulosin Hydrochloride 0.4 mg oral capsules, quantity 30, repackaged by RemedyRepack Inc. The label includes NDC 70518-0179-00, storage instructions (20-25°C), manufacturer information (Rising Pharma, Inc., Allendale, NJ), and a barcode with a QR code. Directions for use refer to the package insert.*

FDA Label Image

Mm2 (Tamsulosin HCl 0.4mg 70518 0179 01)

Tamsulosin Hydrochloride 0.4 mg oral capsules label showing a quantity of 90 capsules. The label indicates prescription use only, NDC 70518-0179-01, manufactured by Rising Pharma, Inc., Allendale, NJ, and repackaged by RemedyRepack Inc., Indiana, PA. It includes storage instructions and advises users to see the package insert for directions.*

FDA Label Image

Mm3 (Tamsulosin HCl 0.4mg 70518 0179 02)

Label for Tamsulosin Hydrochloride 0.4 mg oral capsules showing quantity of 28. The label includes manufacturer as RemedyRepack Inc. and barcode, NDC number 70518-0179-02, along with storage instructions and directions to see package insert. The label features RemedyRepack logo in purple.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

A line graph depicting mean plasma concentrations of Tamsulosin Hydrochloride in ng/mL over time (hours) following a single 0.4 mg oral dose under fasted and fed conditions in eight subjects. The graph compares plasma concentration-time profiles for the drug under different nutritional states.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

A line graph titled 'Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1' showing mean change over treatment duration in weeks (0 to 13) plus LOCF for three groups: 0.8 mg treatment, 0.4 mg treatment, and placebo. The y-axis represents mean change values ranging from 0 to -11. The graph tracks symptom score reduction over time for the three groups, with distinct markers and lines for each treatment.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

A line graph showing mean change from baseline in total AUA symptom score over 13 weeks for a treatment study. The x-axis represents duration of treatment in weeks, and the y-axis shows mean change in symptom score. Three lines represent treatment groups: 0.8 mg dosage (circles), 0.4 mg dosage (triangles), and placebo (squares). Mean symptom scores decrease over time for all groups, with treatment groups showing greater reductions than placebo.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

A line graph titled 'Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1' showing mean change in mL/sec on the y-axis versus duration of treatment in weeks on the x-axis. It compares three treatments: 0.8 mg (circle markers), 0.4 mg (triangle markers), and placebo (square markers), depicting mean changes over periods from baseline through 13 weeks and last observation carried forward (LOCF).*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

A line graph titled 'Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2' showing mean change in peak urine flow rate over a treatment duration of up to 13 weeks. It compares three treatments: 0.8 mg, 0.4 mg, and placebo, with mean change (mL/sec) on the y-axis and duration of treatment (weeks) on the x-axis. Treatment with 0.8 mg shows the highest mean increase, followed by 0.4 mg, then placebo over time.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure of Tamsulosin Hydrochloride showing its molecular components and bonding arrangement as depicted in the image.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.